Guggenheim raised the firm’s price target on Ardent Health (ARDT) to $18 from $16 and keeps a Buy rating on the shares after Ardent reported Q1 EBITDA slightly above consensus. Ardent shares remain “uniquely attractive” in the context of the current policy backdrop, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health Partners, Inc. Shows Strong Q1 Performance with Growth Potential Amidst Strategic Opportunities
- Ardent Health Partners Sees Revenue Growth in Q1 2025
- Ardent Health reports Q1 EPS 29c, consensus 21c
- Ardent Health backs FY25 EPS view $1.73-$2.01, consensus $1.91
- Is ARDT a Buy, Before Earnings?